Please login to the form below

Not currently logged in
Email:
Password:

ABPI says UK must stay strong in research

Stephen Whitehead, CEO of the ABPI, has said continued government support is needed if the UK is to remain a leader in research following a report published by the Department for Business, Innovation and Skills

Stephen Whitehead, CEO of the ABPI, has said continued government support is needed if the UK is to remain a leader in research.

The call follows a report published by the Department for Business, Innovation and Skills (BIS) that shows UK research accounts for 14 per cent of the world's most highly-cited articles, the second largest share after the US.

Whitehead said it was important not to focus on past and present successes in science, however, and that the UK must keep up with a research industry that is growing on an international scale, especially in emerging markets.

He said: "If the UK is to remain at the forefront then we must to continue to encourage investment – the risks involved with research must be rewarded, and we will need to see the continued support of the government if this is to happen."

The International Comparative Performance of the UK Research Base 2011 report, launched by Universities and Science Minister David Willetts, also described the current UK research base as the 'most productive in the world' being highly mobile, internationally competitive and diverse.

Announcing the report, Willets said the government was "committed" to maintaining the UK's position in science and research.

He said: "That's exactly why we protected the £4.6bn science and research budget and have invested nearly an additional £300m in science capital projects over the past year."

BIS has the International Comparative Performance of the UK Research Base 2011 report available to download.

20th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics